Sincalide

Diagnostic sincalide is administered intravenously, either by injection or a timed infusion.

Sincalide reproduces the biologically active C-terminal eight residues of cholecystokinin, the gut hormone that promotes post-meal gallbladder emptying. Kinevac creates a controlled response during imaging or diagnostic sampling. It has been approved in the US since 1976.

CCK-receptor activation contracts the gallbladder, relaxes the sphincter of Oddi, stimulates pancreatic enzymes and increases intestinal motility. During nuclear gallbladder imaging, clinicians calculate the fraction of tracer expelled—the ejection fraction.

Administration method matters. Studies of a standardized, slower infusion lasting about one hour support more reproducible ejection fractions and a normal lower limit near 38%. Rapid injection produces more cramping and less reliable measurements. Other diagnostic uses stimulate pancreatic secretion for sampling or speed barium through the small bowel.

FDA approved Kinevac in 1976 to stimulate gallbladder contraction, stimulate pancreatic secretion—often alongside secretin—and shorten small-bowel imaging by accelerating barium transit.

Clinicians administer sincalide as part of a specific diagnostic study: measuring gallbladder function, obtaining stimulated pancreatic samples or shortening intestinal radiologic imaging. Its purpose and infusion protocol depend on the test.

Common reactions include abdominal pain or cramping, nausea, an urge to defecate, flushing and dizziness. Pregnancy requires caution because uterine contractions may be stimulated. Intestinal obstruction is a contraindication.